| 23/12/2022 |
LAST WEEK IN REVIEW |
Dhriti.Gupta@Eversana.com |
|
| 22/12/2022 |
ICER Publishes Draft Evidence Report Evaluating Emerging Therapies for Alzheimer’s Disease |
raechel.pusateri@eversana.com |
|
| 22/12/2022 |
In Formal Request, Alzheimer’s Association Asks CMS to Reconsider Aduhelm Coverage Decision |
raechel.pusateri@eversana.com |
|
| 22/12/2022 |
NPPA Finalizes Framework for Suo Moto Corrections in Notified Prices to Improve Pricing Process |
Dhriti.Gupta@Eversana.com |
|
| 22/12/2022 |
New Zealand to Source Alternative Diabetes Treatment in Response to Global Trulicity Shortage |
raechel.pusateri@eversana.com |
|
| 22/12/2022 |
Happy Holidays & Warm Wishes for a Healthy New Year! |
anna.smith@eversana.com |
|
| 22/12/2022 |
India's NPPA Fixes Ceiling Price of 12 Formulations Under DPCO, 2013 |
Dhriti.Gupta@Eversana.com |
|
| 22/12/2022 |
Brazilian Health System and Novartis Agree to Innovative Payment Model to Cover Cost of Zolgensma |
raechel.pusateri@eversana.com |
|
| 22/12/2022 |
FDA Oks Lupin to Market Generic Version of Briviact |
Dhriti.Gupta@Eversana.com |
|
| 22/12/2022 |
EU Backs 2 AZ Oncology Drugs |
anna.smith@eversana.com |
|
| 22/12/2022 |
ICER Issues Final Report Assessing Clinical Effectiveness and Value of Gene Therapies Targeting Hemophilia |
raechel.pusateri@eversana.com |
|
| 22/12/2022 |
EUnetHTA 21 Publishes 5 More Deliverables |
anna.smith@eversana.com |
|
| 22/12/2022 |
FDA Approves Roche’s Actemra for Hospitalized COVID-19 Patients |
anna.smith@eversana.com |
|
| 22/12/2022 |
EC Grants ODD to Henlius’ Hansizhuang |
anna.smith@eversana.com |
|
| 22/12/2022 |
Generic Association Celebrates Lauterbach for “Finally” Tackling Supply Issues |
anna.smith@eversana.com |
|
| 22/12/2022 |
Over 4 Crores Health Cards Digitized in India Under ABDM |
Dhriti.Gupta@Eversana.com |
|
| 21/12/2022 |
India's NPPA Revises Ceiling Price of 107 Formulations Under DPCO, 2013 |
Dhriti.Gupta@Eversana.com |
|
| 21/12/2022 |
India's NPPA Fixes Ceiling Price of 10 Formulations Under DPCO, 2013 |
Dhriti.Gupta@Eversana.com |
|
| 21/12/2022 |
Final “Yes” from Chamber Paves Way for AIFA Reform |
anna.smith@eversana.com |
|
| 21/12/2022 |
ICER Issues Revised Evidence Report Evaluating Multiple Sclerosis Treatments |
raechel.pusateri@eversana.com |
|
| 21/12/2022 |
U.S. Spending Package Addresses Accelerated Approval, Other Health Care Reforms |
raechel.pusateri@eversana.com |
|
| 21/12/2022 |
Kite Pharma Announces Acquisition of Tmunity Therapeutics |
raechel.pusateri@eversana.com |
|
| 21/12/2022 |
EU Approves Zynlonta for R/R DLBCL |
anna.smith@eversana.com |
|
| 21/12/2022 |
Glenmark Launches Novel Triple FDC Teneligliptin with Pioglitazone & Metformin in India |
Dhriti.Gupta@Eversana.com |
|
| 21/12/2022 |
ICER Updates Health-Benefit Price Benchmark for Paxlovid |
raechel.pusateri@eversana.com |
|
| 21/12/2022 |
CSL Behring Selects Orsini Specialty as Hemgenix Distribution Partner |
raechel.pusateri@eversana.com |
|
| 21/12/2022 |
UK MHRA Accepts EQRX’s MAA for Sugemalimab & Chemo Combo to Treat Metastatic NSCLC |
Dhriti.Gupta@Eversana.com |
|
| 21/12/2022 |
After Delays, Ontario to Establish Biosimilar Switching Policy |
raechel.pusateri@eversana.com |
|
| 21/12/2022 |
Japan OKs Breyanzi as 2nd-line R/R Large B-cell Lymphoma Treatment |
anna.smith@eversana.com |
|
| 21/12/2022 |
Egypt to Produce 76 Cancer Drugs Locally in the First Half of 2023 |
Dhriti.Gupta@Eversana.com |
|
| 21/12/2022 |
German Health Minister Announces More Major Changes to System |
anna.smith@eversana.com |
|
| 20/12/2022 |
FDA Approves New Indication for Eagle Pharmaceuticals’ Pemfexy |
raechel.pusateri@eversana.com |
|
| 20/12/2022 |
France Backs Orphan Drug Xenpozyme |
anna.smith@eversana.com |
|
| 20/12/2022 |
Insulin Shortage in Pakistan, Experts Claim of Price Hike Up to 53% |
Dhriti.Gupta@Eversana.com |
|
| 20/12/2022 |
Brazilian Pilot Project Successfully Streamlines Post-registration Requests for Biologics |
rachel.yalisove@eversana.com |
|
| 20/12/2022 |
Catalyst Pharmaceuticals to Purchase U.S. Commercial Rights to Eisai’s Fycompa CIII |
raechel.pusateri@eversana.com |
|
| 20/12/2022 |
Atara’s Ebvallo Receives EC Approval as First EBV+ PTLD Treatment |
Dhriti.Gupta@Eversana.com |
|
| 20/12/2022 |
France Maintains Reimbursement of Remicade for Pediatric Crohn’s |
anna.smith@eversana.com |
|
| 20/12/2022 |
New Zealand Funds Janssen’s Stelara and Remicade |
rachel.yalisove@eversana.com |
|
| 20/12/2022 |
NICE Places Enhertu in CDF for More Advanced Breast Cancer Patients |
anna.smith@eversana.com |
|
| 20/12/2022 |
Ono Collaborates with PrecisionLife to Discover Novel Therapies for CNS Diseases |
Dhriti.Gupta@Eversana.com |
|
| 20/12/2022 |
Eisai, Washington University Collaborate to Create Novel Treatments for Neurodegenerative Disorders |
Dhriti.Gupta@Eversana.com |
|
| 20/12/2022 |
Chuikyo Greenlights FY2023 Off-year Price Revision Rules, Pharma Reacts |
anna.smith@eversana.com |
|
| 20/12/2022 |
Australia Updates Medicines Policy For First Time in More Than 20 Years |
rachel.yalisove@eversana.com |
|
| 20/12/2022 |
EU Approves Enhertu for 2nd Line Treatment of HER2+ Gastric or GEJ Cancer |
Dhriti.Gupta@Eversana.com |
|
| 20/12/2022 |
Daiichi Sankyo Launches Ezharmia in Japan for T-Cell Leukemia-Lymphoma |
anna.smith@eversana.com |
|
| 19/12/2022 |
Sosei Inks Licensing Deal with Lilly in Diabetes & Metabolic Disease |
anna.smith@eversana.com |
|
| 19/12/2022 |
Indian Council of Medical Research to Conduct Research in ‘Therapeutics for Inherited Rare Diseases’ |
Dhriti.Gupta@Eversana.com |
|
| 19/12/2022 |
Korea Reveals ICER Evaluations for First Time in 15 Years |
rachel.yalisove@eversana.com |
|
| 19/12/2022 |
IMC Supports Delay in PMPRB Guideline Implementation |
rachel.yalisove@eversana.com |
|
| 19/12/2022 |
FDA Approves Ferring Pharma’s Gene Therapy for Bladder Cancer |
raechel.pusateri@eversana.com |
|
| 19/12/2022 |
Vraylar Receives FDA Nod for Treatment of Major Depressive Disorder |
raechel.pusateri@eversana.com |
|
| 19/12/2022 |
TLV Includes Farydak in High-cost Protection for Certain MM Patients |
Luke.Hannaford@Eversana.com |
|
| 19/12/2022 |
Sanofi Expands Collaboration With Innate for Natural Killer Cell Therapeutics in Oncology |
Luke.Hannaford@Eversana.com |
|
| 19/12/2022 |
LAST WEEK IN REVIEW |
Dhriti.Gupta@Eversana.com |
|
| 19/12/2022 |
G-BA Gives Orphan Drug Brineura Highest Rating in Latest Meeting |
anna.smith@eversana.com |
|
| 19/12/2022 |
Europe Launches Cross-border Project to Improve Affordability & Accessibility of Innovation |
anna.smith@eversana.com |
|
| 19/12/2022 |
COVID-19 Vaccines Saved Australia’s Economy, Finds New Study |
rachel.yalisove@eversana.com |
|
| 19/12/2022 |
FDA Lifts Partial Clinical Hold for Pediatric Patients in Bluebird Bio Sickle Cell Disease Studies |
raechel.pusateri@eversana.com |
|
| 19/12/2022 |
Shilpa Medicare Launches Capebel 1000mg Dispersible Tablets to Treat Metastatic Breast Cancer in India |
Dhriti.Gupta@Eversana.com |
|
| 19/12/2022 |
Oxford’s Ebola Vaccine Manufactured by Serum Institute India Shipped to Uganda |
Dhriti.Gupta@Eversana.com |
|
| 19/12/2022 |
U.S. Congress Revisits Antimicrobial Netflix Model |
rachel.yalisove@eversana.com |
|
| 19/12/2022 |
Madrigal’s NASH Candidate Achieves Promising Phase 3 Results |
rachel.yalisove@eversana.com |
|
| 19/12/2022 |
France in Favor of Reimbursing Kymriah for Certain Follicular Lymphoma Patients |
Luke.Hannaford@Eversana.com |
|
| 19/12/2022 |
France Backs Keytruda as Adjuvant Treatment for Stage IIB, IIC, or III Melanoma Following Complete Resection |
Luke.Hannaford@Eversana.com |
|
| 19/12/2022 |
Janssen Withdraws EU Application Seeking Approval of Imbruvica for Patients With Untreated MCL |
Luke.Hannaford@Eversana.com |
|
| 19/12/2022 |
Lotus Pharmaceuticals Acquires Eli Lilly’s Cancer Drug Alimta in Taiwan |
Dhriti.Gupta@Eversana.com |
|
| 19/12/2022 |
Prescryptive Health and Eli Lilly to Offer Value-Based Payment Model for Insulin |
raechel.pusateri@eversana.com |
|
| 19/12/2022 |
Attralus Announces Orphan Drug Designation for AT-01 in Europe |
raechel.pusateri@eversana.com |
|
| 19/12/2022 |
FDA Greenlights Glenmark’s Generic Equivalent of Cardene Hypertension Drug |
Dhriti.Gupta@Eversana.com |
|
| 19/12/2022 |
Reata & Lilly Withdraw Drugs from EMA |
anna.smith@eversana.com |
|
| 16/12/2022 |
European Commission Lays Out Further Info on EU Pharmaceutical Strategy |
anna.smith@eversana.com |
|
| 16/12/2022 |
AbbVie Leaves PhRMA & Other Industry Groups |
rachel.yalisove@eversana.com |
|
| 16/12/2022 |
Fimea Publishes Assessment of Vyvgart for Myasthenia Gravis |
Luke.Hannaford@Eversana.com |
|
| 16/12/2022 |
48% Of Listed Products in Japan to Face Price Cuts Under Off-year Revision |
anna.smith@eversana.com |
|
| 16/12/2022 |
ABPI Warns 'Skyrocketing' VPAS Clawback Puts UK Sector at Risk |
Luke.Hannaford@Eversana.com |
|
| 16/12/2022 |
Pakistan’s Health Ministry Seeks Investigation into Non-Opening of LCs |
Dhriti.Gupta@Eversana.com |
|
| 16/12/2022 |
Spanish Association Calls for Direct Collaboration with Health Administrations to Improve Financing of Drugs |
Luke.Hannaford@Eversana.com |
|
| 16/12/2022 |
Fimea Publishes Economic Assessment of Kapruvia for Severe Pruritus |
Luke.Hannaford@Eversana.com |
|
| 16/12/2022 |
CHMP Recommends 5 New Drugs |
Luke.Hannaford@Eversana.com |
|
| 16/12/2022 |
FDA Grants Orphan Drug Designation to Ocugen’s Investigational Rare Retinal Disease Drug |
raechel.pusateri@eversana.com |
|
| 16/12/2022 |
Torrent Pharma Ties Up with BI India to Co-market its Anti-diabetic Drug |
Dhriti.Gupta@Eversana.com |
|
| 16/12/2022 |
Federal Judge Upholds Arkansas State Law Protecting the Use of Contract Pharmacies under 340B |
raechel.pusateri@eversana.com |
|
| 16/12/2022 |
Nexium, Lexapro, Bonviva Face Generic Entry in Japan |
anna.smith@eversana.com |
|
| 16/12/2022 |
France Grants Early Access to Amvuttra for hATTR Amyloidosis |
Luke.Hannaford@Eversana.com |
|
| 16/12/2022 |
New York’s Community Care Health Orgs Brace for Loss in Federal Reimbursement Funding |
rachel.yalisove@eversana.com |
|
| 15/12/2022 |
NHS Director Hails Commercial Deals & VPAS, Despite Industry Concern |
anna.smith@eversana.com |
|
| 15/12/2022 |
TLV Forecasts SEK 2.4B in Savings From Side Agreements in 2022 |
Luke.Hannaford@Eversana.com |
|
| 15/12/2022 |
Takeda Launches Cinryze in India to Treat Rare Genetic Condition Hereditary Angioedema |
Dhriti.Gupta@Eversana.com |
|
| 15/12/2022 |
JB Pharma Inks Deal with Glenmark to Acquire Razel Franchise for India & Nepal |
Dhriti.Gupta@Eversana.com |
|
| 15/12/2022 |
Amid Nationwide Shortage, Alberta, Canada Secures Imported Pain Meds from Turkey |
rachel.yalisove@eversana.com |
|
| 15/12/2022 |
Wales Recommends Votubia for Tuberous Sclerosis Complex |
Luke.Hannaford@Eversana.com |
|
| 15/12/2022 |
EU Backs Sanofi’s Dupixent for Prurigo Nodularis |
anna.smith@eversana.com |
|
| 15/12/2022 |
AEMPS Issues Recommendations to Alleviate Supply Problems with Fibrinolytic Drugs |
Luke.Hannaford@Eversana.com |
|
| 15/12/2022 |
State Prisons Gain Purchase Power for Gilead’s Hep C Drugs |
rachel.yalisove@eversana.com |
|
| 15/12/2022 |
Innovent Biologics and LG Chem Enter License Agreement Regarding Tigulixostat |
raechel.pusateri@eversana.com |
|
| 15/12/2022 |
Angelini Pharma Launches Ontozry in France for Epilepsy |
Luke.Hannaford@Eversana.com |
|
| 15/12/2022 |
50% of EMIG Companies to Reduce Supply to UK in 2022 |
anna.smith@eversana.com |
|
| 15/12/2022 |
FDA Approves Fresenius Biosimilar Referencing Humira |
raechel.pusateri@eversana.com |
|
| 15/12/2022 |
FDA Grants Orphan Drug Designation to PharmaTher’s Ketamine |
raechel.pusateri@eversana.com |
|
